[Profound Medical Corp. (Globe Newswire)] Profound Medical Corp. announced that it has received 510(k) clearance from the US FDA for the Company’s Thermal Boost module for use in conjunction with TULSA-PRO®.

[Journal of Clinical Investigation] Researchers demonstrated that the DNA-PK holoenzyme was part of the androgen receptor variant 7 (AR-V7) interactome and was a key regulator of AR-V-mediated transcription and cell growth in models of advanced prostate cancer.

[Acta Biomaterialia] The combination of smart nanocarrier and sequential '405-580 nm' irradiation strategy exhibited good photodynamic therapy efficacy against 2D 22RV1 prostate cancer cells as well as 3D cancer cell spheroids.

[British Journal of Cancer] Using shRNA-mediated PDE4D7 knockdown in LNCaP cells, scientists replicated clinical observations that diminished PDE4D7 expression promoted an aggressive prostate cancer phenotype.

[Molecular Cancer Research] Investigators found that circular RNA DDIT4 (circDDIT4) was downregulated in prostate cancer and functioned as a tumor suppressor during prostate cancer progression.

[Biomedical Materials] Microfibrillar matrices were fabricated as 3D spherical and disc-shaped scaffolds with highly interconnected pores and the potential of the newly developed scaffolds for developing prostate cancer model has been investigated.

[The Prostate] Polyphyllin I (PPI), one of the steroidal saponins in paris polyphylla, has been shown to have an anticancer effect. Researchers investigated the role and mechanism of PPI in CRPC cell ferroptosis.

[International Journal of Radiation Biology] The authors investigated the effectiveness and molecular characteristics of docetaxel and radiation combination therapy in vitro.

[Journal of Molecular Histology] Investigators detected the toxicity of sennoside A (SA) on PC3 and DU 145 cells via CCK-8. The effects of SA on growth, apoptosis, and autophagy were determined through additional examinations.

[Kaohsiung Journal Of Medical Sciences] To investigate the molecular mechanisms underlying the effects of nimotuzumab on prostate cancer development, the authors focused on the miR-199a-5p and miR-214-3p miRNA clusters.

[Oncogene] Scientists discuss how expression of the splicing regulators ESRP1 and ESRP2, and how their role as “masterminds” of epithelial splicing patterns, have been identified as markers of aggressively proliferating prostate primary tumors.

[University of South Carolina] The Keck School of Medicine of University of South Carolina (USC) has received funding from the National Institutes of Health as part of a five-year, $50.3 million “multi-omics” study of human health and disease involving six sites.